Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vofopitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vofopitant SCHEMBL30522777 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8901341 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL30522778 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8431760 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL7062769 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL2996010 | 1.00 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL8316732 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL310793 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL5153521 | 0.99 | TACR1 (1.00) | TACR1 | |
| Vofopitant SCHEMBL29711142 | 0.99 | TACR1 (1.00) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 357 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-4255400-B1 | NEUROKININ INHIBITORS SUCH AS APREPITANT FOR TREATING NON SMALL CELL LUNG CARCINOMA WITHOUT MUTATIONS | PLUS VITECH S L (ES) | 2025-12-24 | — | — | EP | claimed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | claimed |
| US-12390454-B2 | Use and composition for protection against organophosphorus poisoning | CLARENCE SMITH KATHLEEN E (US) | 2025-08-19 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| EP-2966448-B1 | METHOD FOR THE PREDICTION OR PROGNOSIS OF THE RESPONSE OF A HUMAN SUBJECT SUFFERING FROM CANCER TO TREATMENT WITH AN ANTAGONIST OF THE NK1 RECEPTOR | SERVICIO ANDALUZ DE SALUD (ES) | 2025-03-05 | — | — | EP | claimed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024194352-A1 | DEUTERATED P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-26 | — | — | WO | claimed |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-12 | — | — | US | claimed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | claimed |
| US-6329401-B1 | PREVENTION OR TREATMENT OF SLEEP DISORDER; BY ADMINISTERING A CNS PENETRATING NEUROKININ-1 RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-12-11 | — | — | US | claimed |
| US-6274604-B1 | ADMINISTERING A NEUROKININ-1 RECEPTOR ANTAGONIST TO ACHIEVE A CIRCADIAN RYTHM PHASE-SHIFTING TO IMPROVE THE QUALITY OF SLEEP | MERCK & CO., INC. | 2001-08-14 | — | — | US | claimed |
| US-6242446-B1 | Method for treating attention deficit disorder | MERCK & CO., INC. | 2001-06-05 | — | — | US | claimed |
| EP-0912174-A4 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO INC (US) | 2000-12-06 | — | — | EP | claimed |
| JP-2000514455-A | — | — | 2000-10-31 | — | — | JP | claimed |
| US-6034105-A | NEUROKININ RECEPTOR ANTAGONIST; SLEEP DISORDERS | MERCK & CO., INC. (US) | 2000-03-07 | — | — | US | claimed |
| EP-0912174-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | claimed |
| EP-0720609-B1 | 3-(5-TETRAZOLYL-BENZYL)AMINO-PIPERIDINE DERIVATIVES AND ANTAGONISTS OF TACHYKININS | GLAXO GROUP LTD (GB) | 1998-11-11 | — | — | EP | claimed |
| WO-1998002158-A1 | ALTERATION OF CIRCADIAN RHYTHMICITY WITH A TACHYKININ ANTAGONIST | MERCK & CO., INC. (US) | 1998-01-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366639-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | TACR1 670/4885 |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MTNR1A, PROKR1, NTSR2 | TACR1 45/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | TACR1 226/4885 |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | P2RX3, P2RX1, P2RX5 | TACR1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.